NASDAQ · Analyst Forecast

NewAmsterdam Pharma Company N.V. (NAMS) Stock Forecast & Price Target

$19.39 NASDAQ: NAMS Market Cap $2.33B

Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering NewAmsterdam Pharma Company N.V. (NAMS), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For NewAmsterdam Pharma Company N.V., analysts forecast revenue rising from $26.99M in 2025 to $1.11B in 2030; the average estimate for 2030 earnings per share is $3.16; with published estimates ranging from $0.08 to $8.86; 11 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$19.39
Consensus targetThe average of the price targets analysts have published.$53.75
Median targetThe middle target, less affected by a single outlier.$54.50
Highest targetThe most optimistic published target.$61.00
Lowest targetThe most pessimistic published target.$45.00
Difference from priceHow far the consensus target sits from today’s price.+177.2%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$23.90M$26.99M$38.80M9
2026$24.15M$40.04M$61.43M10
2027$15.87M$67.46M$156.24M11
2028$66.67M$302.55M$638.96M11
2029$180.00M$719.38M$1.72B5
2030$276.83M$1.11B$2.64B5

Earnings per share forecast

YearLowAverageHighAnalysts
2025−$1.69−$1.54−$1.209
2026−$1.68−$1.54−$1.3910
2027−$2.73−$1.94−$1.2811
2028−$2.02−$0.91$0.7411
2029$0.03$1.16$3.265
2030$0.08$3.16$8.865

NewAmsterdam Pharma Company N.V. (NAMS) forecast — frequently asked questions

What is the analyst price target for NewAmsterdam Pharma Company N.V.?

Analysts covering NewAmsterdam Pharma Company N.V. (NAMS) have a consensus price target of $53.75, 177.2% above the current price of $19.39. Published targets range from $45.00 to $61.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for NewAmsterdam Pharma Company N.V.'s earnings?

The average analyst estimate for NewAmsterdam Pharma Company N.V. (NAMS) earnings per share in 2030 is 3.16, with individual estimates between 0.08 and 8.86.

How much revenue is NewAmsterdam Pharma Company N.V. expected to make?

Analysts forecast NewAmsterdam Pharma Company N.V. (NAMS) revenue of $1.11B in 2030, based on 5 published estimates.

How many analysts cover NAMS?

11 analysts contribute estimates for NewAmsterdam Pharma Company N.V. (NAMS). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.